EZH2 and prostate carcinoma: We identified 43 cell-differentiation markers targeted by PRC2 (either showing EZH2-repression in prostate cancer or PRC2-silencing in ESC), presenting a significant enrichment among RA-induced genes and PRC2-silencing targets (p = 1e-8, odds ratio = 3).